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Mutations  designed by analysis of the Rous sarcoma 
virus (RSV) and human immunodeficiency virus (H1V)- 
1 protease  (PR)  crystal  structures  were introduced  into 
1) the  substrate  binding pocket, 2) the  substrate  en- 
closing “flaps,”  and 3) surface loops of RSV PR. Each 
mutant  PR  was  expressed  in Escherichia  coli. Changes 
in  activity  were  detected by following  cleavage of a 
truncated (NC-PR)  precursor  polypeptide  in E. coli and 
cleavage of synthetic  peptide  substrates  representing 
RSV and HIV-1 PR  cleavage  sites in  vitro. Mutations 
in  the  substrate  binding  pocket exchanged  amino  acid 
residues located close to  the  substrate  in  the HIV-1 PR 
for  structurally  equivalent residues in the RSV PR. 
Changing  histidine 65 to glycine (H65C)  gave an in- 
active enzyme, while  a double mutant  R105P,G106V, 
as well as the  triple  mutant,  H65G,R105P,G106V, 
produced  enzymes which showed significant  activity 
toward a substrate  that  represented a HIV-1  cleavage 
site. Mutating the catalytic aspartate (D37S) or an 
adjacent  conserved  alanine to  threonine  (A40T),  pro- 
duced inactive enzymes. In  contrast,  the  substitution 
A40S was  active,  but showed a  reduced rate of catal- 
ysis. Mutations in the flaps of conserved glycines 
(G69L,  G70L)  produced  inactive PRs. Two  extended 
RSV PR  surface loops were  shortened  to  the  size  found 
in HIV- 1 PR  and  resulted  in  drastically  reduced  activ- 
ity. These results have confirmed some of the basic 
predictions made from  structural models but  have  also 
revealed  unexpected  roles and  interactions  in  the  pro- 
tein. 
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Recent interest in the retroviral aspartic protease stems 
from its essential role in retroviral replication and  its  potential 
as  a  therapeutic  target to block HIV’ infection (for reviews 
see  Refs. 1 and 2). The  PR  is responsible in uiuo for processing 
viral gag and gug-pol precursor polypeptides, whose products 
are required for the production of mature infectious virus 
particles (3-5). To do so, the  PR must specifically  cleave 7-9 
unique sequences, depending upon the virus. At present, it is 
not clear how the PR recognizes such a diverse group of 
substrates. The minimum sequence required for cleavage, 
defined by structural and biochemical studies, is 7 amino 
acids (P4-P3’); inspection of these various sequences (6) does 
not reveal a consensus. The only obvious recurrent  feature is 
that amino acids at or near the cleavage sites tend to be 
hydrophobic. 
The RSV and HIV-1 PRs recognize different substrates 
and  exhibit very different catalytic rates (7-9); the  HIV-1 PR 
is approximately 10-fold more active than  the RSV  enzyme. 
To begin to understand the relationship between PR structure 
and function, we have compared the high resolution crystal- 
lographic structures of the RSV (10, 11) and  HIV-1 (12-19) 
PRs for similarities and differences that might be related to 
specificity. This information has been  used to select targets 
for site-directed mutational analysis, which for this report 
includes the surface loops, the substrate-enclosing flap region, 
and the active site of the RSV PR. Some mutational analyses 
of the RSV and HIV PRs have  been reported previously  (20- 
23). Substitution of one or both of the catalytic aspartate 
residue(s) has always resulted in an inactive enzyme. In 
addition, Loeb et ul. (20) have identified three regions of the 
HIV-1 PR  that are very sensitive to amino acid substitution. 
These regions include the amino acids surrounding the  cata- 
lytic triad,  the flaps, and  a region in HIV-1 PR corresponding 
to T74 to R87. All of these regions are expected to include 
amino acids directly involved in  substrate binding. 
Despite differences in molecular size and sequence, the 
three-dimensional structures of the two PRs resemble each 
other, as well as cellular aspartic proteases such as pepsin 
(24), rhizopuspepsin (25),  and endothiapepsin (26). The retro- 
viral PRs are unique, however, since they are only half as 
The abbreviations used are: HIV, human immunodeficiency virus; 
RSV, Rous sarcoma virus; AMV, avian myeloblastosis virus; PR, 
retroviral protease; NC, nucleocapsid; SDS, sodium dodecyl sulfate; 
HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid. All 
amino acids and numbers placed in italics refer to  the sequence of the 
HIV-1  PR. 
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large as  the cellular enzymes and must dimerize to form a 
catalytically active enzyme. The  structural alignment of the 
HIV and RSV enzymes (shown in Fig. lA) reveals 31 identical 
residues and 9 additional conservative amino acid substitu- 
tions. Since the HIV-1 PR has 99 residues, compared to 124 
for the RSV PR, parts of the  latter structure do not correspond 
to  the former. Most of these differences are localized to two 
surface loops and the flaps which are smaller in  the HIV-1 
PR (Fig. 1B). 
The  structural similarity between the two PRs is especially 
evident around the active site where 44 C ,  backbone atoms 
superimpose within a 0.5-A root mean square deviation (11). 
This similarity allowed us to use structural models for HIV-1 
PR complexed to substrate-based peptide inhibitors (14-19) 
to predict amino acid residues in the RSV PR substrate 
binding pocket. Thirteen residues were observed to be in close 
proximity to a  substrate-based  inhibitor  in HIV-1 PR and  are 
indicated by bold letters in Fig. lA. Nine of these residues 
were identical in the RSV PR. Three of these residues were 
sufficiently different to be candidates that may discriminate 
between substrates of the two PRs. To  test  this hypothesis, 
amino acids found in the HIV PR were introduced into 
comparable structural positions in the RSV enzyme  (Fig. 1B). 
Analysis of the activity of these  altered RSV PRs on peptide 
substrates representing known RSV and HIV-1 cleavage sites 
verified that  the candidate residues do influence selection of 
substrate by PR. 
EXPERIMENTAL  PROCEDURES 
Bacterial Cells and DNA Constructs-The expression vectors used 
for the mutagenesis, pPR  and  pNC-PR (Fig. 2),  were as previously 
described (21). They  contain, respectively, the RSV protease and  the 
nucleocapsid-protease fusion protein (precursor p23). The viral genes 
are under the control of a  temperature-sensitive X cI repressor. Two 
strains of Escherichia coli, AR68 and MC1061,  were used for cloning 
and expression. In MC1061 cells, the repressor is supplied in trans 
from the plasmid pRK24&Its, while in AR68 cells, the repressor is 
supplied by an integrated copy of the X genome containing cI857. The 
construction of plasmid pPR-GGGG-PR and details for purification 
of linked PR dimers are  as previously described (28). The plasmid 
pPR-GGGG-PRA(A59-M73) was created by oligodeoxynucleotide- 
directed mutagenesis of the  parent vector pPR-GGGG-PR. The plas- 
mid pPR-GGGG-PR(H1V) was constructed by substituting the distal 
DNA subunit of PR from pPR-GGGG-PR with a DNA fragment 
encoding the HIV-1 PR from the vector pPROT/RT (a gift from 
Stuart LeGrice, Case Western Reserve University). 
Bacterial Cell Growth and Induction-The bacteria were  grown at 
30 "C in M9 medium containing 0.5% glucose and 0.5% Casamino 
acids or in YT media. Expression from the PL promoter was induced 
by shifting the culture to 42 "C at midlog phase. Cells were collected 
3 h postinduction, or as indicated, and protein was analyzed by 
polyacrylamide gel electrophoresis (27) and immunoblotting (21, 28) 
using antisera directed against NC or PR. 
Mutagenesis-Site-directed oligodeoxynucleotide mutagenesis was 
used as previously described (21) to introduce amino acid changes 
(substitutions and/or deletions) into the protease coding region of 
pPR  and pNC-PR. Oligodeoxynucleotides used for mutagenesis are 
pPR and pNC-PR (PuuI) and gapped DNA from the expression 
shown in Fig.  3. The oligodeoxynucleotides were mixed with linearized 
vectors (pPR BglII and BssHII; pNC-PR BssHII and BarnHI). To 
construct pNC-PR (H65G,R105P,G106V), the  mutant plasmid pNC- 
PR (H65G) was digested with EcoRI and BglII, and  the fragment 
containing the H65G substitution was subcloned into EcoRI/BgZII- 
digested and purified pNC-PR (R105P,G106V). The same strategy 
was used to construct pPR (H65G,R105P,G106V) from pPR (H65G) 
and  pPR (R105P,G106V). 
Preparation of Retrouiral Proteases-Inclusion bodies were pre- 
pared from E. coli induced for expression of the RSV PR  as previously 
described (21). The cells were disrupted with EDTA and lysozyme 
followed by treatment with Triton X-100 or sonication. The pellet 
was collected and washed by sequential suspension and centrifugation 
(6-8 times), first with 25% sucrose, 10 mM 2-mercaptoethanol and 
25 mM sodium phosphate, pH 7.5, then with 1-2 M urea. The inclusion 
bodies were solubilized in 8 M urea (with 150 mM 2-mercaptoethanol), 
and  the protease was refolded by dialysis (0.5-1  mg  of protein/ml) a t  
23 "C against a decreasing concentration of urea (4,2,  and 1 M for 2 
h  each). The final dialysis (against 25 mM sodium phosphate, pH 7.5, 
150 mM NaCl, and 10 mM 2-mercaptoethanol) was overnight. The 
clarified soluble fraction containing active PR was stored at 4 "C. 
The preparations were at least 95% pure as determined by SDS- 
polyacrylamide gel electrophoresis with Coomassie staining (28). Pro- 
tein  concentration was determined using the Bio-Rad Protein Assay 
Kit (Bio-Rad Laboratories) and bovine serum albumin as a  standard. 
In some experiments, wild type and  mutant  PR subunits were  mixed 
in 8 M urea and renatured together. 
Purified HIV-1 PR was a generous gift from Dr. C. Z. Giam (Dept. 
of Medicine, Case Western Reserve University). Purified HIV-2 PR 
was generously provided by S. LeGrice (Dept. of Medicine, Case 
Western Reserve University). AMV PR, prepared from viral particles 
by the procedure of Alexander et al. (29), was obtained from Molecular 
Genetic Resources (Tampa, FL). The RSV and AMV PRs, which 
differ in primary sequence by two amino acids, are enzymatically 
indistinguishable and have been used interchangeably in these  stud- 
ies. 
The efficiency of refolding of the bacterial derived RSV PR varied 
from preparation to preparation. Therefore, the specific activity of 
all refolded enzymes was assessed by the method of Tomasselli et al. 
(30), which involves titrating  PR concentrations  against  a nanomolar 
or stoichiometric inhibitor and extrapolating to  the inhibitor concen- 
tration  that yields complete loss in activity. The inhibitor used was 
PPCV(phe-statine)AMTM (31). The RSV recombinant PRs refolded 
with an efficiency that varied between 20 and 40%, while the HIV 
PR refolded with close to 100% efficiency. 
Peptides-Peptides were synthesized and purified as previously 
described (28). Lyophilized preparations were dissolved in 1 mM 2- 
mercaptoethanol. Concentrations were determined by amino acid 
composition analysis. In addition to the amino acids assumed to 
interact with the protease, all peptides contained an N-terminal Pro 
(to prevent reaction with fluorescamine), and 2  C-terminal arginines 
(to improve solubility). The peptides used in the present study are 
listed in  Table I. 
Proteolytic Assay-The assay was based on the reaction of fluores- 
camine (Pierce) with primary amines produced at  the P1' position 
after cleavage (21). The assay mixture (25 pl) contained 2.4 M NaCl 
(1 M for the HIV PRs), 0.1 M sodium phosphate  (pH 5.9), 0.2 mM 2- 
mercaptoethanol, 50-300 nM protease (active dimers according to 
titration),  and 10-400 p~ peptide. The reaction was started by adding 
the protease and stopped by adding 175 pl of 0.5 M sodium borate 
(pH 8.5). The incubation time (37 "C) varied from 1 to 45  min. With 
HIV-1 PR, incubation times longer than 8 min were avoided, as  this 
enzyme had a half-life of approximately 20 min when incubated in 
the absence of substrate (presumably due to autocatalysis). 
The amount of cleaved peptide was determined by adding 20 pl of 
0.05% (w/v) fluorescamine, mixing vigorously, and measuring the net 
increase in fluorescence intensity a t  excitation and emission wave- 
lengths of 386 and 477 nm, respectively, using a  Perkin-Elmer LS- 
5B Spectrofluorometer with both excitation and emission slits set  at 
10 nm. Fluorescence was converted to nanomoles of product formed 
using a standard curve obtained by reacting fluorescamine with the 
peptide FQAY (CH,N)PLR. This peptide was used as a  standard since 
TABLE I 
Peptides used as PR substrates 
Virus cleavage site 
Location of Peptide sequence" 
RSV gagMA-p2 PTSCY-HCGTRR 
gag CA - NCb PLIM-AWNRR 
gag NC - PR PPAVS - LAMTFdRR 
p o l  PR-RT PATVL - TVALRR 
p o l  IN-p4 PLFA-GISDRR 
HIV - 1 gag CA-NCa PARVL -AEAMRR 
gag CA-NCb PATIM-MQRERR 
gag NC - p6a PGNF-LQSRR 
gag NC - p6b PRQAN-FLGKRR 
p o l  RT- IN PRKIL-FLLXRR 
"Hyphens indicate the scissile bond. In addition to the P4-P3' 
amino acids assumed to interact with the  PR, N-terminal prolines 
were added to avoid reactivity with fluorescamine and C-terminal 
arginines to improve solubility. 
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it was  found that the reaction of fluorescamine  with short peptides 
was  somewhat different from the reaction  with  free  amino  acids  or 
proteins. The presence of  high concentrations of peptides  quenched 
the fluorescence  readings.  Measurements  made  in the presence of 200 
p~ peptide or above  were therefore  corrected  for  quenching: 7.5% for 
200 phi and proportionally more at higher peptide concentrations. 
The extent of quenching was found to be approximately the same 
with  all substrates used  in this study. All assays were  performed  in 
triplicate using  several  independent  PR preparations. The standard 
deviation was  less than 10%. Correct  cleavage of selected substrates 
was  verified  by HPLC  separation of products  and  amino  acid  com- 
position  analysis.  Two of the HIV-1  peptides (Table I) contain  lysine 
residues with amino groups. The pK. values of these groups are 
approximately 10.5 so that  at pH 8.5 they are mostly  protonated  and 
therefore do not  react  efficiently  with the fluorescamine.  However, 
an  increase  in the background  fluorescence of these substrates of 2- 
to 3-fold  over  peptides  without  lysine  residues was noted.  Nonethe- 
less,  activity  measurements  reported  here were at least  10-fold  above 
background  fluorescence  in  each  case. 
Kinetic Anulysis-For each substrate peptide, 5-7 different  concen- 
trations were tested and the reaction was  stopped  before 20% of the 
substrate was  cleaved. Within that limit, the reaction  was  shown to 
be linear  with  time,  implying that the turnover could be used as a 
measure of initial velocity. Kinetic  parameters were determined by 
fitting the velocity versus substrate concentration data to the Mi- 
chaelis-Menten  equation  using the program NFIT (Island Products, 
Galveston, TX). The R2 values were greater than 0.99. Standard 
deviations for the K,,, values were less than 20% and  for the kc, values 
less than 10%. 
Zmmunoblotting-Proteins  from  uninduced E. coli extracts or  from 
E. coli  induced to express  NC-PR  fusion  protein  were  separated on 
SDS-18% polyacrylamide gels (28), visualized, and transferred to 
membranes as previously  described (28). The membranes  were incu- 
bated  with  precleared  rabbit anti-RSV PR serum (diluted 1/5000), 
washed, and incubated with biotinylated goat anti-rabbit antibody 
followed  by the Vectastain Elite  reagent,  and the peroxidase  reaction 
was visualized using Indophane blue. Where indicated, the mem- 
branes were incubated  with  precleared  rabbit  anti-RSV NC or PR 
serum  in  phosphate-buffered  saline  containing  0.1%  Tween 20 and 
1% bovine serum albumin for 1 h at 37 "C. After washing  twice  with 
phosphate-buffered  saline  containing 0.1% Tween 20, the membranes 
were incubated  with 20-50 pCi of lZ6I-labeled  protein G (Amersham) 
in phosphate-buffered saline containing 0.1% Tween 20 and 1% 
bovine  serum  albumin  for 1 h at room temperature. The membranes 
were then washed three times as above, air-dried, and exposed to 
Kodak X-OMAT AR-5 x-ray film at -70 "C with an intensifying 
screen  for 10-20 h. 
Molecular  Modeling-The crystal structures of the native RSV PR 
(11) and HIV-1 PR, as well as of the complexes of the latter with 
inhibitorb) (14-19), were examined on an Evans and Sutherland 
PS390 computer graphics system using the program FRODO (32). 
The residues  forming the subsites were determined  directly  for the 
HIV-1 PR complexed  with inhibitors, and the corresponding  residues 
in RSV PR were obtained from the structural and sequence align- 
ments. The structural superimposition of the C, atoms from the 
subunits of RSV and HIV-1 PRs (33, 34) was used to deduce the 
residues to be  deleted  in the extended  surface  loops of RSV PR and 
in the flaps. 
RESULTS 
Rationale for  PR  Mutations 
The superimposed crystal structures of HIV-1 and RSV 
PRs were compared  in  order  to  locate regions that would be 
expected to  influence substrate  binding  and  catalysis  or  to 
have other interactions with the polyprotein precursors or 
other  mature  viral  proteins.  The  active  site residues of the 
two PRs  are  found  in  virtually  identical  conformations.  Much 
of their  subunit  structure  is very similar  as well, despite  the 
fact  that  the two enzymes differ in specificity and  rates of 
catalysis. Their role in  regulation of the  viral life cycle may 
also differ since  the RSV PR is present  in  both  the gag and 
gag-pol precursors and thus may have other functions in 
addition to proteolytic cleavage of precursors. Based upon 
this  structural  analysis, a series of mutations  in (a) the  active 
site, ( b )  the  substrate  binding pocket, and  (c)  on  the  protein 
surface have  been designed to explore structure/function  re- 
lationships of the  PR  and  its role in  viral replication. Fig. 1B 
shows the  location of the  altered  amino  acids  and  structures. 
It should be noted that the retroviral PR is a homodimer. 
Thus, when mutations are introduced into the monomeric 
subunit,  they  are  de facto  double mutations  in  the  native  PR. 
This is true except for the mutations placed into a P R  in 
which the  subunits  are covalently  linked. 
Actiue Site Mutants-Several types of active  site  mutations 
have  been  constructed.  These include substituting  serines for 
the  catalytic  aspartic acid  residues  (D37) to prove that  these 
residues are  essential for  catalysis. Serine was  chosen  since it 
was not expected to drastically alter the structure of the 
catalytic  site.  Serine  and  threonine were also substituted for 
alanine 40. This alanine residue is highly conserved in all 
retroviral  PRs.  In  the closely related  nonviral  aspartic  pro- 
teases,  serine  and  threonine  are conserved in  the  correspond- 
ing positions. It  has  been suggested that  this difference may 
account  for  the lower pH optimum of the cellular enzymes 
(35, 36). 
An important  feature of the  active  site  is  the  flap  structure, 
an  extended surface loop that lies over the  substrate  binding 
region (Fig. 1B). It is present in all aspartic proteases and 
may affect substrate  binding  and/or catalysis. In retroviral 
PRs there are two flaps, one per subunit in the dimer, in 
contrast to the single flap of nonviral aspartic proteases. 
However, the flap  sizes are  not conserved. For  instance,  the 
RSV P R  flaps  contain  three more amino acids than  the  HIV- 
1 P R  flaps. RSV PR  mutants were constructed which con- 
tained  either a single flap  or which substituted  the  smaller 
HIV-1 flaps for those found in  the RSV PR.  The  flaps  are 
also  characterized by a series of conserved glycines, which are 
presumed to provide flexibility to the loop conformation. 
These residues may also have a steric role in binding sub- 
strate. In order to test the importance of these residues, 
glycine 69 and 70 were mutated  to bulkier  leucine residues. 
RSV Specificity Mutants-The  substrate  binding region of 
the retroviral protease was initially defined by modeling a 
peptide  substrate based on  the position of the  inhibitor  in  the 
co-crystal  structure of rhizopuspepsin  with  a  reduced peptide 
inhibitor (25, 33). This was later  substantiated by examina- 
tion of the  crystal  structures of HIV-1 P R  with inhibitors 
(14-19). This  analysis  indicated  that  the peptide  backbones 
of the  inhibitors were in  the  same  extended  conformations 
(19). This observation suggested that hydrogen bond  inter- 
actions  with  the backbone of substrates were similar  for all 
aspartyl  proteases with the exception that  the single  flap of 
the nonviral aspartyl proteases makes only 2 to 3 contacts 
with the backbone of the inhibitor while the flaps of the 
retroviral P R  make at  least 6 contacts (42). Thus,  substrate 
specificity  may arise  through  interactions between the  amino 
acid  side chains from  residues of the  substrate  and enzyme. 
Superposition of the dimers of HIV-1 and RSV PR and 
examination of the  HIV-1  PR  inhibitor  binding regions 
showed that  there were at  least 13 amino acid  residues  in the 
substrate  binding  pocket sufficiently close to  an inhibitor (14- 
18) to allow side chain  interactions. A  comparison of these 13 
HIV-1 residues with  those  found  in  comparable positions in 
the RSV P R  indicated  that 9 were identical (Fig. L4). The 4 
which were different were 144-V32, H65-G48, R105-P81, and 
G106-V82, in  RSV  and  HIV-1  PRs, respectively. As the  first 
of these involved two closely related  amino acids, the  other 3 
residues were chosen  as  targets for  mutagenesis. Three RSV 
P R  constructs were made, one  containing H65G, one contain- 
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A STRUCTURAL ALIGNMENT OF THE RSV AND HIV-1  PRs 
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FIG. 1. Structure and sequence comparison of the RSV and HIV-1 PRs. A ,  structural alignment of the 
RSV and HIV-1 PRs. The numbers of amino acids for the RSV and HIV-1 PRS are indicated. Secondary structure 
elements (CY helices and p structure)  are indicated above and below the sequences for the RSV and HIV-1  PRs, 
respectively. Thirteen amino acid residues of HIV-1 PR with side chains  in close proximity to a substrate-based 
inhibitor  are shown in bold letters. Of these, four are different in RSV (also shown in bold letters). B,  tracing of the 
C, backbone of the RSV PR showing sites of mutations. The two subunits of the RSV PR are drawn in the medium 
l ine  (top) and thin line  (bottom). Residues belonging to  the flap were  modeled in the top  subunit only. This modeling 
was for illustrative purposes only and may not represent the true  structure.  Mutations and deletions discussed in 
this paper are identified in the top  subunit only. The deletions are shown in dashed  lines. Amino acid substitution 
mutations next to  the deletions are  not shown separately. Side chains of the mutated residues, or main chain 
atoms for glycines, are shown in thick lines. More detail about the mutations is provided in Fig. 3. 
ing R105P and G106V, and one containing all three  substi- 
tutions. 
Surface Loops-The other obvious structural difference be- 
tween the two enzymes is that  the RSV PR has two extended 
surface loops from residues 19 to 28 (loop A) and from 86 to 
90 (loop B), compared to shorter loops present in HIV PR. 
Many other retroviral PRs show the shorter loops character- 
istic of HIV-1 PR  at these two regions (37). Exceptions are 
bovine leukemia virus and human T-cell leukemia virus, 
where loop A is longer than in the HIV-1 PR but  shorter than 
in  the RSV PR, while  loop B has the same length as  the RSV 
PR. Therefore, one might predict that deletion of the "extra" 
residues in the RSV surface loops, which lie far from the 
active site, might have little effect on catalysis but could affect 
viral replication via the loss of interactions with other do- 
mains of the polyprotein. To test this hypothesis, shorter 
loops  were introduced into the RSV PR. In one set of con- 
structs, T18GA(N19-R28)S29G and A(N86-L91)E92G, resi- 
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dues were removed and  substitutions were made to include 
glycine at  the predicted turn regions as occurs in HIV-1  PR. 
Preparation of Mutant  PR and PR-containing Precursor 
Fragments 
Fig. 2 shows a map of the region in RSV  DNA that contains 
the PR coding sequences. The indicated fragments were 
cloned in an E. coli plasmid vector downstream from the 
bacteriophage X PL promoter and an ATG initiator codon 
(21). The  pPR clone expresses a  protein that is predicted to 
be identical with the viral PR with the exception of the 
initiator methionine (which is often removed in bacterial 
cells). The pNC-PR expresses a protein that contains PR 
upstream from the NC sequences as normally occurs in the 
viral gag precursor protein. The pPR-GGGG-PR clone ex- 
presses a PR dimer linked by 4 glycine residues. The plasmid 
expression clones were subjected to  site-directed mutagenesis, 
as described under “Experimental Procedures,” to introduce 
the mutations listed in Fig. 3. 
Expression and Analysis of Mutant  PRs in Bacterial Extracts 
We have shown previously that  the  NC-PR protein  pro- 
duced by the clone pNC-PR described in Fig. 2 processes itself 
in E. coli to form mature NC and PR products (38). Fig. 4 
shows a comparison of products observed in  extracts of bac- 
teria that express NC-PR precursor fragments with different 
catalytic site  mutations. The viral proteins were detected by 
immunoblot analysis using an anti-PR serum. Extracts of 
cells that express the wild type precursor fragment contained 
both NC-PR and PR, as expected. The same two proteins 
were detected in the extracts from cells expressing the NC- 
PR(A40S)  mutant, although in  this case there appeared to be 
PPR 
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FIG. 2. Molecular clones of PR and NC-PR. pPR  and pNC- 
PR are E. coli expression clones describedpreviously (21) that contain 
the viral PR or nucleocapsid and protease (NC-PR) genes, respec- 
tively. The numbers correspond to  the Rous sarcoma virus sequence. 
PLOL is the leftward promoter derived from X phage DNA. pPR- 
GGGG-PR is an E. coli expression clone described previously (28) that 
contains a covalently linked PR dimer. GGGG (hatched box) indicates 
a 4-glycine linker that fuses the two PR subunits. pPR-GGGG- 
PRAfA59-M73) is an expression plasmid that contains  a covalently 
linked PR with a  truncated  flap  in the indicated subunit. pPR-GGGG- 
PR(HZV) is an expression plasmid containing  a covalently linked PR 
dimer with one RSV and one HIV subunit. The initiation codon 
provided by the expression vector is indicated (ATG). The genetically 
engineered amber stop codon (TAG) is shown at  the  end of the  PR 
domain. 
less of the  PR product made. Free PR was not detected in 
cells expressing the other  mutant proteins, including A40T 
and D37S. In  these cases, there was  some antibody-reactive 
protein in intermediate positions that probably reflects diges- 
tion by bacterial proteases. We also note that  the  mutant NC- 
PR proteins migrate slightly differently from the wild type 
protein in this gel system. 
Plusticity of the PR Substrate  Binding Pocket 
A similar analysis was carried out with mutant  PRs con- 
taining substitutions and/or deletions in the flap region of 
the RSV PR. This region appears to be very sensitive to 
mutation as indicated by the results from bacterial lysates 
shown in Fig. 5. Substitutions at positions 65, 69, and 70, 
exchange of the HIV-1 PR flaps for those in RSV, or removal 
of one of the RSV flaps (pPR-GGGG-PRA(A59-M73) in Fig. 
2) produced inactive PRs. Also, a mosaic PR (pPR-GGGG- 
PR(H1V) in Fig. 2) containing one HIV-1 and one RSV 
subunit was inactive (data  not shown). 
The enzymatic studies of the RSV PR(H65G)  mutant were 
of particular interest. When substituted singly, glycine at 
position 65 produces an RSV enzyme which  was inactive on 
the RSV NC-PR precursor. However, if this mutation was 
combined with two other RSV to HIV-1 PR amino acid 
exchanges, R105P and  Gl06V, activity on this  substrate was 
restored (Fig. 6). The RSV PR mutant containing only 
R105P,G106V was active. These  results indicate that unfa- 
vorable conformational changes in the flaps introduced by 
H65G can be compensated by additional changes in the sub- 
strate binding pocket. 
Purification of Mutant  PRs 
While analysis of cleavage of the NC-PR precursor in 
bacterial extracts provides a rapid screen for mutations that 
change PR activity, accurate quantitation of these effects is 
not possible. To facilitate such studies, selected PR  mutants 
were expressed as  the free  enzyme and purified from bacterial 
extracts.  With the exception of HIV-2 PR, all of the  proteins 
were recovered from the inclusion body fraction. The  PRs 
were solubilized by suspension in urea and renatured by 
sequential dialysis. A RSV wild type PR prepared by this 
procedure had the same substrate preference as  the  PR puri- 
fied  from AMV. However, the efficiency of refolding varied 
from preparation  to  preparation.  In order to correct for dif- 
ferences in estimates of the specific activities of the different 
PR preparations, renatured PRs were titrated with a sub- 
strate-based  inhibitor,  and the activities were related to  the 
number of active dimers as described under “Experimental 
Procedures.” The  titration experiments indicated that with 
the  better bacterial-derived preparations 30-40%  of the pro- 
tein was  folded correctly. 
Activity of PR  Mutants 
A comparison of the activity with an NC-PR peptide sub- 
strate of the purified RSV PRs containing substitutions at 
positions 37, 40, 65, and 69 and 70 or deletions of surface 
loops is summarized in Table 11. Of the 7  mutant  proteins 
analyzed, only the A40S protein had significant activity, 
consistent with the immunoblot analysis shown in Fig.  4. Its 
activity was  23% that of the wild type, a difference attribut- 
able to a decrease in kc,,; there was no detectable change in 
its K,,, for binding substrate (data not shown). Despite the 
change in catalytic  rate, the relative activity of this  mutant 
on various RSV-based substrates followed that of the wild 
type enzyme (data  not shown). However, the A40S PR  ap- 
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1. Active  site  and bindina DOCket mutations; 
Ollgonucleotlde 
5’ ATCACCGCGCTGTTC&CKTGGAGCGGACATC 3’ 
5’ CTGTTGGACTCTGGATCCGACATCACTATTATT 3’ 
5’ GCTGTTGGACTCTGGTACCGACATCACTATTATT 3’ 
SCCGCAGTAGCTATmAGTGAGTATCCTAGGAAGA3’ 
2. FlaD  mutations: 
Ollgonucleotlde 
STGGAGGCCGCGAACCCCCAGATCGGTGGGATAGGAGGGGGA 3’
5’ ATCCATGGGATAGGATT-CCCATGCGAAAA 3’ 
STTGGCCAGTGATGGAGATAGGGGGGATAGGAGGGGGY 
5’ CGATTGGCCAGTGATGCCTAAGATGATCGGGGGGATAGGAGGGGGGA 3’
5’ TGATGGAGCGAAAATCCCGGGACATGATAGAGTTGG 3’ 
3.  Surface loor, mutations: 
Ollgonucleollde 
5’ TAGGGTCATTCTGASZGIGTGTATATCACCGCGC 3’ 
5’ CCTTGGTTAGGGTCATCCTAGGCGGCGTGTATATCACCGCGC 3’ 
5’GTTGGGGGTTATTGAGAGG.‘XICTGCTCCTCTTCCCCG3’ 
5’AGAGTTGGGGGTTATTG.G?&GECCCTGCTCCTCTTCC 3’ 
Mutallon Restrlctlon Enzyme x 
D37s Sac I 
A40S BamH I 
A40T Kpn I 
R105P.Gl06V Kpn I 
Mutallon Restrlctlon Enzyme 
H65G Bstx I 
G69L.G70L Ase I 
A591,A60G.A(N61-H65) Nco 1. 
E%tP,A59K,A60Mb(N61-063)H65G NCO I. 
A(A59M73) Sma I 
Mutation Reslrlctlon Enzyme 
A(N19.RZS) spel 
TlSG,A(N19-R2S)S29G Avrll 
A(NS6.L91) stu I 
A(NS6-L91)E92G Aat I1 
ti A new  restriction  site  was  introduced  in  each  oligonucleotide (s e undelined  nucleotides) to  allow  srceening of mutant  PR-containing  plasmids. 
Loss of the  original Nco I restriction  site. 
FIG. 3. RSV PR mutations. Oligodeoxynucleotides used to place mutations into the pPR and pNC-PR 
plasmids by site-directed mutagenesis are  as indicated. New restriction enzyme sites  (underlined) were introduced 
to facilitate identification of mutated clones. Mutations are listed by the amino acid and position number of the 
RSV PR followed by the substituted  amino acid. Deletion mutations are indicated by A followed  by the position 




FIG. 4. Effect of active site mutations on PR activity. Im- 
munoblotting of cell lysates from induced bacterial cultures express- 
ing NC-PR and NC-PR mutant proteins containing NC-PR, NC- 
PR(D37S), and NC-PR(A40S or A40T). E. coli were  grown at  30 “C 
in minimal medium to  an  ODm of 0.8 and  then at  42 “C for 2 or 4 h 
to induce expression of the cloned DNAs. Samples of bacteria from 
uninduced and induced cultures were fractionated  on an 18% poly- 
acrylamide-SDS gel. AMV PR was included as a marker. After 
electrophoresis, proteins were transferred to  an Immobilon membrane 
and PR was detected using rabbit anti-PR serum and peroxidase 
staining as described under  “Experimental Procedures.” The numbers 
above the lanes indicate time (h) of incubation a t  the induction 
temperature. * denotes position of PR where applicable. 
peared to be slightly more active than wild type at  pH values 
below  5.5 (Fig. 7). 
No activity was detected with the purified D37S, A40T, 
H65G, and G69L,  G70L PRs (Table 11). When the denatured 
D37S, A40T and G69L, G70L proteins were  mixed with 
equimolar or twice equimolar amounts of denatured wild type 
AMV PR, respectively, and refolded as described under “EX- 
perimental Procedures,” the amount of active wild type PR 
activity recovered was as predicted for a binomial distribution 
of the various dimer  forms (Table 111). This indicates that  the 
mutant  subunits were able to form stoichiometric complexes 
with those of  wild type protein. Therefore, we conclude that 
their lack of activity is not due to incorrect folding. 
Activity  of PR Mutants with Modified Surface Loops 
Mutant  PRs with one or two of the surface loops shortened 
were  also  purified.  If one of the loops  was shortened, then  the 
mutant exhibited only 2 to 3% of the activity associated with 
the wild type RSV PR (Table 11). If both of the loops were 
shortened, no activity was detected. When introduced into an 
infectious virus DNA  clone, the amount of residual activity 
found in these “loopless” PRs was insufficient to support 
normal processing of gag precursor polypeptides in uiuo, and 
infectious progeny virions were thus  not obtained (data not 
shown). 
Mutations of Residues Involved in Substrate Recognition 
Purification of RSV PR mutants, R105P,G106V and 
H65G,R105P,G106V, allowed us to test their activities on 
both RSV and HIV peptide substrates  (Table  I).  The H65G 
was inactive on all substrates tested (data not shown). In 
contrast, the R105P,G106V  enzyme had the same activity as 
the wild type PR on all RSV substrates (Table IV). In 
addition, it was indistinguishable from wild type in its 
requirements for pH  and  temperature  and in its  salt 
dependency (data not shown). The R105P,G106V mutant 
differed significantly from wild type with at least one HIV-1 
peptide substrate  (RT-IN), for which it exhibited a 10-fold 
increased  activity  (Table IV). The combined  mutant 
(H65G,R105P,G106V) had about 25% of the activity of the 














FIG. 5. Effect  of  flap mutations on PR activity. Immunoblot 
analysis of NC-PR proteins  containing  flap  mutations in  the  PR  and 
expressed in E. coli. Cell lysates were fractionated on a SDS-15% 
polyacrylamide gel, and  the virus-related proteins were detected with 
rabbit  antiserum directed against the NC (panel A )  or  the  PR (panel 
B )  with ’251-labeled protein G as described under “Experimental 
Procedures.” Molecular size markers in kilodaltons are indicated on 
the left. The positions of NC-PR  and  PR  are indicated  on the right. 
~ ”. 
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FIG. 6. Effect  of substrate binding pocket mutations on PR 
activity. Immunoblot analysis of NC-PR  proteins  containing  sub- 
strate binding pocket mutations and expressed in E. coli. Cell lysates 
were analyzed as described in the legend to Fig. 5 except that only 
anti-PR serum was used to detect  proteins. 
Activities of RSVproteases  with active site or structural mutations 
PR mutation Activity” 
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‘Activity was determined as described under  “Experimental Pro- 
cedures” using mutated RSV PRs  as indicated and  the RSV NC-PR 
peptide  substrate. Activity of the wild type PR is 575 nmol of peptide 
cleaved/min/mg of enzyme. 
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FIG. 7. The pH dependence of AMV and A40S RSV PR. 
AMV PR (46 ng) or RSV PR(A40S) (150  ng) was incubated with the 
NC-PR  peptide substrate using 100 mM citrate for pH 3-7 and 100 
mM HEPES for pH 7.9 instead of sodium phosphate buffer. The  rate 
of cleavage was determined as described under  “Experimental Pro- 
cedures.” 100% activity for the AMV and RSV  A40S PRs is defined 
as 584 and 81 pmol of peptide cleaved, respectively, in 30 min. El, 
AMV PR, ., RSV PR(A40S). 
TABLE 111 
Renaturation mixing experiments with  RSV and mutant PR subunits 
Ratio of wild 
subunits 
PR added” type to mutant PR activityb 




WT + PR(A40T) 
WT + PR(A40T) 
WT + PR(G69L,G70L) 
WT + PR(G69L,G70L) 
WT + PR(D37S) 
WT + PR(D37S) 






1:2  0.27 
1:l 0.77 
1:2  0.29 
1:l 0.41 
1:2  0.21 
a Wild-type RSV and  mutant  PR subunits were solubilized from 
the inclusion body fraction with 8 M urea and renatured  either alone 
or in  mixtures of wild type and  mutant subunits (25-45 pg/ml) as 
described under  “Experimental Procedures.” The molar ratio of the 
wild type to  the  mutant subunits  is as indicated. 
*The activity of the  PR preparations  containing  in each case 0.6 
ng of  wild type subunit  and variable amounts of the  mutant subunits, 
as indicated, were assayed for cleavage of the NC-PR peptide sub- 
strate  as described under  “Experimental Procedures.” 
wild type  on RSV substrates,  but was more active than  the 
wild type  on the HIV-1  RT-IN substrate. If the  amount of 
activity observed with the wild type and  mutant enzymes for 
the HIV-1 RT-IN substrate is normalized to that of the 
RSV NC-PR substrate, then the R105P,G106V and the 
H65G,R105P,G106V PRs had 10- and 20-fold increases in 
activity toward the HIV-1 substrate, respectively. Specific 
cleavage of peptides was independently verified by HPLC 
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TABLE IV 
Activity of wild type and mutant enzymes on peptide  substrates 
containinz RSVand  HIV-1 cleavaee sites 
Protease activity’ 
Substrate RSV 
AMV (R105P, (H65G,R105P, HIV-1  HIV-2 
RSV 
G106V)  ) 
RSV-based substrates* 




IN-p4  2.6 2.9 1.2 3.0 2.2 
7.9 6.4 1.7 13.0 10.9 
14.9 15.1 4.3 41.0 25.4 
12.0 10.7 3.0 7.3 3.4 
HIV-1-based  substrates* 
CA-NCa 0.6 0.4 0.2 114.5 64.8 
CA-NCb 0.2 0.2 0.1 281.1 195.0 
NC-p6a 0.0 0.0 0.0 151.7 121.8 
0.0 0.0 0.0 51.0 52.7 
0.5 4.7 2.8 124.5 166.4 
NC-p6b 
RT-IN 
‘The PR  activity  was  determined by the fluorescamine  reaction  as 
describedunder  “Experimental  Procedures.”  The  activity is the  initial 
rate of turnover in the presence of 100 PM substrate measured as 
molecules of product  formed per active  enzyme  dimer per min. 
The  sequences  are  listed in Table  I. 
TABLE V 
Kinetic  measurements  with  NC-PR  (RSV)  and RT-IN (HIV-1) 
peptide substrates 
Kinetic  values were obtained from Michaelis-Menten  plots of the 
initial velocity versus substrate concentration. Activity was deter- 
mined  using the fluorescamine assay as described  under  “Experimen- 
tal  Procedures.” 
Source of PR Substrate K ,  kt k,,/K, 
p~ min” p ~ ’  min” 
AMV RSV  NC-PR 49 21.6 0.45 
RSV(R105P,G106V) 
RSV(H65G,Rl05P,GlOSV) 
45 19.9 0.44 
77 6.1 0.08 
HIV-1 16 43.8 2.77 
HIV-2 23 29.7 1.29 
AMV HIV-1  RT-IN 98 1.3 0.01 
RSV(R105P,G106V) 100 11.6 0.12 
RSV(H65G,RlO5P,GlO6V) 95 5.5 0.06 
HIV-1 37 170.1 4.65 
HIV-2 42 221.4 5.27 
separation of the products  and amino acid composition analy- 
sis (data  not shown). Little  or no activity for the other four 
HIV-1 substrates was detected with wild type or mutant  PRs 
(Table IV) . 
As a control, each of the peptide substrates was incubated 
with either the purified HIV-1 or HIV-2 PRs. Each HIV-1 
substrate was rapidly cleaved by both HIV enzymes with rates 
that were 10- to 20-fold greater than  that observed with the 
RSV PR for its homologous substrates. While the RSV and 
AMV PRs generally cleaved HIV substrates very inefficiently, 
the HIV PRs cleaved the RSV substrates with rates compa- 
rable to  that of the RSV  enzyme. The best RSV substrate for 
the AMV PR (the  NC-PR  peptide) was also the best RSV 
substrate for the HIV enzymes. 
Kinetic  Analysis of Activity on the RSV NC-PR and the 
HIV-1 RT-IN Substrates 
To determine the nature of the differences in activity 
between the  mutant  and wild type enzymes, a steady state 
kinetic analysis was carried out using the RSV NC-PR  and 
the HIV-1 RT-IN peptide substrates  (Table V). The wild type 
AMV and HIV PRs had K, values for their respective ho- 
mologous substrates in the 16-50 p~ range. Interestingly, the 
HIV PRs bound the RSV substrate more efficiently than  its 
own  homologous substrate.  This is in contrast to  the AMV 
PRs which bound the heterologous substrate less efficiently. 
The binding affinities of the RSV  R105P,G106V and 
H65G,R105P,G106V mutants for the HIV-1 RT-IN  substrate 
were the same as wild type PR.  Thus,  the increased activity 
observed with the  mutant  PRs for this  substrate is solely an 
effect of kcat. A comparison of the efficiency (kat/K,) of the 
R105P,G106Vand the H65G,R105P,G106V PRs for the RSV 
NC-PR or the HIV-1 RT-IN peptide substrates indicated that 
the  mutants were 12- and 6-fold, respectively, more efficient 
on the HIV substrate  than wild type PR. If one normalizes to 
the amount of activity that is observed with the RSV NC-PR 
peptide substrate,  then the relative efficiencies calculated for 
the R105P,G106V and the H65G,R105P,G106V PRs are 12- 
and 34-fold, respectively, more efficient than wild type. These 
results indicate that introduction of amino acids found in the 
substrate binding pockets of HIV-1 PR into the RSV PR 
confers increased relative specificity for an HIV-1  substrate. 
DISCUSSION 
The results of our mutational  studies verify that  the amino 
acids in and  around the catalytic site  triad  and in the flap 
region of the RSV PR are essential for enzymatic activity. 
Consistent with previous studies on avian and  human  retro- 
viruses (20-23), substitution of the catalytic aspartate (D37) 
results in an inactive PR. However, the D37S mutant may be 
useful for biochemical and  structural  studies of PR since its 
overall structure should not be altered. This prediction is 
supported by our observation that when refolded together, 
D37S PR subunits  can form stoichiometric complexes with 
wild type PR subunits. Nonconservative substitutions, such 
as D371, cause conformational distortion of the PR (20). 
Craven et al. (41) also have shown that release of RT from a 
gag-pol precursor polypeptide containing PR mutations by 
exogenously added PR occurs efficiently when the mutation 
in the precursor is D37S but  not when it is D371. Again, this 
suggests that the latter mutation causes distortions in the 
polypeptide structure. 
The catalytic aspartate (D37) residues are  part of a rigid 
structure, held in place by an intricate network of hydrogen 
bonds which are formed with amino acids 38 and 39, as well 
as with the 37-39 active site triad from the other subunit. 
This unique structure is highly conserved in all aspartic 
proteases (1). In retroviral PRs, an alanine residue always 
follows the active site triad. In related cellular proteases, 
serine is found at this position in  the amino domain, whereas 
threonine is predominantly present in the carboxyl domain 
of the enzyme. The  latter is infrequently substituted by serine 
and in one case, that of human renin, by alanine (39). Sielecki 
et al. (35) suggested that  the presence of alanine  rather than 
serine at this position may account for the higher pH optimum 
of human renin compared to other cellular aspartyl proteases, 
since serine or threonine,  but  not  alanine of renin could form 
a hydrogen bond with the catalytic aspartate. Mantafounis 
and Pitts (36) have  made the substitution T218A in chymosin 
B and shown that  this change shifted the  pH optimum for 
activity toward neutral values. Whether a similar situation 
exists in the retroviral PR is not clear. When serine is substi- 
tuted for alanine in the RSV PR, an enzyme is produced 
which is less active than wild type and  its  pH for  maximum 
activity appears to be unchanged. However, this  mutant  PR 
does appear to retain  a greater percentage of its activity at 
acid pH ranges compared to wild type. In  contrast,  threonine 
substitution at position 40 results in an inactive enzyme. 
Molecular modeling of the relevant structures indicates that 
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the A40S substitution  can  take place without steric hindrance 
while that of the A40T cannot (21). Thus  the  latter mutation 
is expected to cause some movement or  rearrangement in the 
backbone atoms  near the catalytic  site which, presumably, is 
unfavorable for binding or catalysis. Loeb et al. (20) have 
introduced 4  amino acid substitutions at  the same conserved 
alanine  in the HIV-1  PR. In  contrast to  the results described 
here, none of these  substitutions, including serine, produced 
an active enzyme. The difference between our results and 
those of Loeb et al. (20) may reflect inherent differences 
between the two PRs or may be due to  their use of a less 
sensitive assay, which  followed precursor cleavage in bacterial 
extracts. 
One of the interesting regions of the  PR molecule contains 
the flaps. Residues in this region interact with the peptide 
substrates  and may exclude water molecules from the catalytic 
site. Unfortunately,  structural information about the flaps in 
the RSV PR is incomplete due to disorder in the crystal 
structure (11). The structure of the flaps in HIV-1 PR is 
known and  they have been shown to move as much as 7 A 
and to change orientation upon substrate binding (14-16). 
Comparison of the amino acid sequence of the flaps of RSV 
to  that  in  the HIV-1 PR shows that those in RSV contain 3 
additional residues (37). Loeb et al. (20) have reported that 
amino acid substitutions in the HIV-1 flap region usually 
inactivate the PR. Our mutational analysis yielded similar 
results. Replacement of the longer RSV flaps with the shorter 
ones from HIV-1, removal of one of the two  RSV flaps (data 
not shown), construction of a mosaic enzyme with RSV and 
HIV-1 PR subunits, and replacing glycines at positions 69 
and 70 with leucines or histidine at position 65 with glycine, 
all produced inactive enzymes. This  last result was not  pre- 
dicted since substitutions at glycine 48 (the  structurally iden- 
tical position in HIV-1 PR  to RSV PR H65) with histidine, 
or 4  other amino acids, produced active enzymes (20). 
Avian retroviral PRs have two extended external loops, one 
of which is larger than any comparable loop found in mam- 
malian retroviral PRs. The presence of these loops in the 
RSV PR may serve a possible structural role in virion core 
assembly since, unlike HIV or Moloney leukemia virus, the 
avian retrovirus PR is synthesized as  part of both gag and 
gag-pol precursors and can be purified from virions in amounts 
equal to that of the capsid structural proteins. Thus, we 
hypothesized that removal of the surface loops of RSV  may 
leave an enzymatically active protein which  may exhibit de- 
fects in formation of mature virus particles. The analysis 
presented here indicates that  the function of these  structures 
is more  complex than first supposed. When the surface loops 
were shortened individually, a nearly inactive enzyme re- 
sulted. When the mutation was placed into an infectious virus 
DNA clone, the level of residual PR activity was insufficient 
to support processing of viral precursor polypeptides in vivo 
(data  not shown). It should be noted that these constructs 
contained  substitutions that placed amino acids found at  the 
turns of the smaller HIV-1 PR surface loops. Without these 
substitutions, the singly deleted surface loop mutants were 
completely inactive. Thus, while surface loops of RSV PR can 
be removed and  a  partially active PR obtained, the enzymes 
are very defective. There  are several possible explanations for 
these results. First, A(N86-L91)E92G removes E92 which 
forms a  salt bridge with the N  terminus of the second subunit 
and is thus  important for stabilizing the dimer structure of 
the PR. Elimination of a salt bridge in the linked dimers 
reduces catalytic activity (28). Second, amino acids in loop A 
form several hydrogen bond interactions with residues at  the 
base of the flap and removal of these may also reduce activity. 
Third, removal of the surface loops exposes amino acids 
normally buried beneath the surface, and  this could create a 
distortion of the polypeptide backbone which might interfere 
with catalytic activity. Finally, there may be some problem 
with folding of this bacterially derived mutant  PR.  Thus, new 
constructs which introduce more limited alterations  into  the 
surface loops  will  have to be analyzed before any conclusion 
of a  structural role for these loops can be made. 
Several amino acids found in  the HIV-1 PR in close prox- 
imity to a bound peptide-based inhibitor were exchanged for 
amino acids in comparable positions in the RSV PR.  These 
mutations were  designed to identify amino acid residues that 
may  be important  determinants for substrate specificity. 
Three  constructs were made, RSV PR(H65G), RSV 
PR(R105P,G106V), and RSV PR(H65G,R105P, G106V). The 
H65G exchange produced an inactive enzyme. Glycine 48 in 
the HIV-1 PR is  involved in forming hydrogen bonds to  the 
peptide backbone of the inhibitor. The  substitution of glycine 
for H65 in RSV PR may  have induced conformational changes 
in the flaps which interfere with interactions with substrate. 
In  contrast, the RSV PR(R105P,G106V) was active. This 
is significant since the amino acids found in the comparable 
structural positions of HIV-1  PR, P81 and V82, respectively, 
are singly very sensitive to amino acid substitution (20). Four 
amino acid substitutions for P81, including arginine, resulted 
in inactive enzymes. Some substitutions of HIV-1 V82, how- 
ever, appeared to be tolerated, although substitution of gly- 
cine, the amino acid found in RSV PR, was not (20). These 
results highlight the need to make multiple amino acid sub- 
stitutions in the substrate binding pocket to understand  their 
significance. This is illustrated again with the striking obser- 
vation that combining the H65G substitution, which inacti- 
vated the RSV PR, with the 105 and 106 substitutions  partly 
restored activity to  the RSV PR. 
Examination of the  substrate specificity of the RSV 
PR(R105P,G106V) and RSV PR(H65G,R105P,G106V) indi- 
cated that  there was a significant increase in activity toward 
the HIV-1 RT-IN peptide substrate with both enzymes. A 
steady state kinetic analysis of these PRs indicated that  the 
increase was due solely to  an increase in catalytic rate; there 
was  no appreciable effect on the binding of substrate. From 
these results, we conclude that  the substitution of HIV amino 
acid residues found in positions comparable to RSV PR 105 
and 106 and at 105,  106, and 65 imparts the ability to cleave 
a HIV substrate. It should be noted, however, that four other 
HIV-1  substrates were either  not cleaved or were  cleaved at 
low rates by the wild type and  the  mutant RSV PRs. The 
reason for inducing only partial HIV-1 PR-like behavior in 
the RSV PR  mutants is provided by an analysis of NC-PR 
cleavage site  substrates with single amino acid substitutions 
at the  P4  to P3’ positions in the accompanying manuscript 
(40). 
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Note Added in Proof-Ido et al. (Ido, E., He-ping, H., Kezdy, F. J., 
and Tang, J.  (1991) J. Bwl. Chem. 266,24359-24366) have reported 
that  the A285 substitution in  HIV-1 PR results in an active enzyme 
with a lower pK value. These results are consistent with the A40S 
mutant presented here. 
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